Latest Conference Articles

May 14th 2014, 1:00pm

ASCO Annual Meeting

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

April 9th 2014, 8:44am

AACR Annual Meeting

A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles

April 7th 2014, 12:07pm

AACR Annual Meeting

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

April 7th 2014, 12:02pm

AACR Annual Meeting

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

April 7th 2014, 11:31am

AACR Annual Meeting

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

April 7th 2014, 6:42am

AACR Annual Meeting

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer

April 7th 2014, 6:40am

AACR Annual Meeting

The combination of palbociclib and letrozole more than doubled PFS and showed a non–statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.

April 7th 2014, 6:00am

AACR Annual Meeting

The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.

March 17th 2014, 11:53am

Interdisciplinary Prostate Cancer Congress

Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013

March 17th 2014, 7:42am

Interdisciplinary Prostate Cancer Congress

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

March 17th 2014, 7:20am

Interdisciplinary Prostate Cancer Congress

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.

March 17th 2014, 6:59am

Interdisciplinary Prostate Cancer Congress

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.

March 17th 2014, 6:38am

Interdisciplinary Prostate Cancer Congress

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

March 14th 2014, 7:19am

Interdisciplinary Prostate Cancer Congress

Insights about PSA screening, genomics, and what's new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual IPCC.

March 10th 2014, 9:14am

PER® Miami Breast Cancer Conference

New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.

March 10th 2014, 8:59am

PER® Miami Breast Cancer Conference

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.

March 10th 2014, 8:46am

PER® Miami Breast Cancer Conference

The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.

March 10th 2014, 7:22am

PER® Miami Breast Cancer Conference

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

March 8th 2014, 1:46pm

PER® Miami Breast Cancer Conference

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.

March 8th 2014, 10:54am

PER® Miami Breast Cancer Conference

Success rates for lumpectomies or mastectomies are high with respect to survival, with up to 98% long-term survival rates for surgery and/or radiotherapy, but what if similar results could be achieved by substituting targeted medications for therapy?